Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Neurofaciodigitorenal syndrome is a rare, multiple developmental anomalies syndrome characterized by neurological abnormalities (including megalencephaly, hypotonia, intellectual disability, abnormal EEG), dysmorphic facial features (high prominent forehead, grooved nasal tip, ptosis, ear anomalies) and acrorenal defects (such as triphalangism, broad halluces, unilateral renal agenesis). Additionally, intrauterine growth restriction, short stature and congenital heart defects may be associated. There have been no further descriptions in the literature since 1997.
Biomarker and diagnostic research for neurofaciodigitorenal syndrome has been reported in the published literature.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for neurofaciodigitorenal syndrome.
32 publications have been identified in PubMed for neurofaciodigitorenal syndrome. Research spans Review / Meta-Analysis (34%), Epidemiology / Natural History (28%), and Diagnostic / Biomarker (16%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 11 | 34% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 2:01 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
9 |
28% |
Testing and diagnosis research | 5 | 16% |
Patient case studies | 4 | 13% |
Clinical study results | 2 | 6% |
Other research | 1 | 3% |
de Carvalho JF (2026). [PMID: 41436900](https://pubmed.ncbi.nlm.nih.gov/41436900/). *Rheumatol Ther*. [Review / Meta-Analysis]
Freire de Carvalho J (2026). [PMID: 41973124](https://pubmed.ncbi.nlm.nih.gov/41973124/). *Z Rheumatol*. [Review / Meta-Analysis]
Correia PRB (2026). [PMID: 41919827](https://pubmed.ncbi.nlm.nih.gov/41919827/). *Codas*. [Review / Meta-Analysis]
Freire YA (2026). [PMID: 41453590](https://pubmed.ncbi.nlm.nih.gov/41453590/). *Physiol Behav*. [Epidemiology / Natural History]
de Carvalho JF (2026). [PMID: 42105054](https://pubmed.ncbi.nlm.nih.gov/42105054/). *Rheumatol Ther*. [Review / Meta-Analysis]
Kant T (2026). [PMID: 42167899](https://pubmed.ncbi.nlm.nih.gov/42167899/). *BMJ Paediatr Open*. [Diagnostic / Biomarker]
Freire I (2026). [PMID: 42194608](https://pubmed.ncbi.nlm.nih.gov/42194608/). *J Clin Med*. [Review / Meta-Analysis]
Dun-Dery F (2025). [PMID: 39004300](https://pubmed.ncbi.nlm.nih.gov/39004300/). *Acad Pediatr*. [Epidemiology / Natural History]
Xie J (2025). [PMID: 40063967](https://pubmed.ncbi.nlm.nih.gov/40063967/). *Pediatr Infect Dis J*. [Epidemiology / Natural History]
Freire YA (2025). [PMID: 40819014](https://pubmed.ncbi.nlm.nih.gov/40819014/). *BMC Geriatr*. [Diagnostic / Biomarker]